NCT03576417: Phase 3: (NIVOPOSTOP) - Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

First Posted	2018-07-03
Trial status	Active, not recruiting
Sponsor	Groupe Oncologie Radiotherapie Tete et Cou
Abstract Presentation	NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. Meeting Abstract: 2025 ASCO Annual Meeting II Head and Neck Cancer - June 04, 2025 Click here for details
Press Release	GORTEC Announces New Trial Success for Head and Neck Cancer Treatment Jan 07, 2025 Click here for details
Peer-reviewed journal publication
FDA
NCCN

NCT03576417: Phase 3: (NIVOPOSTOP) - Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

(A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP))

Official Title:

A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck

Intervention / Treatment:

Drug: Cisplatin

Drug: Nivolumab

Radiation: RT

Other Study ID Numbers:

GORTEC 2018-01

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT03576417